PPQ-102 is a pyramido-pyrrolo-quinoxalinedione that inhibits the cystic fibrosis transmembrane conductance regulator (CFTR) channel. PPQ-102 exhibits nephroprotective and anti-fibrotic activities, decreasing the size of pre-formed kidney cysts in animal models of polycystic kidney disease.
| Cas No. | 931706-15-9 |
|---|---|
| Purity | ≥98% |
| Formula | C26H22N4O3 |
| Formula Wt. | 438.49 |
| IUPAC Name | 7,9-Dimethyl-6-(5-methyl-2-furyl)-11-phenyl-6,7-dihydropyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9H)-dione |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | P6264 Info Sheet PDF |
|---|
Snyder DS, Tradtrantip L, Yao C, et al. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem. 2011 Aug 11;54(15):5468-77. PMID: 21707078.
Tradtrantip L, Sonawane ND, Namkung W, et al. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009 Oct 22;52(20):6447-55. PMID: 19785436.
